ABSTRACT
Primary percutaneous coronary intervention (PCI) with drug eluting stent (DESs) is nowadays the gold standard treatment for patients presenting with scaffold thrombosis (ST)-segment elevation myocardial infarction (STEMI). Patients suffering from a STEMI are often young and therefore with long life expectancy. STEMI patients may benefit more from temporary polymeric caging than from permanent stent implantation. Vasoconstriction of coronary arteries and the presence of thrombus are common features in the context of STEMI. These features should be taken into consideration to correctly select the scaffold size. Antiplatelet regimen is a critical issue of bioresorbable scaffolds (BRSs) in STEMI. Clinical experience of BRSs implantation in STEMI is currently limited. Available data suggest good acute and midterm performance although acute scaffold thrombosis rate appears to be higher-than-expected in a few registries. New generation BRSs may overcome most current technical pitfalls and may improve clinical outcomes.
